EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Oncology
Reference51 articles.
1. High frequency of mutations of the PIK3CA gene in human cancers;Samuels;Science,2004
2. PI3K inhibitors as new cancer therapeutics: implications for clinical trial design;Massacesi;OncoTargets Ther.,2016
3. Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study;Vansteenkiste;J. Thorac. Oncol.,2015
4. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC);Tan,2020
5. Mechanisms of Polycomb gene silencing: knowns and unknowns;Simon;Nat. Rev. Mol. Cell Biol.,2009
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Methionine Restriction Reduces Lung Cancer Progression and Increases Chemotherapy Response;2024-06-29
2. EZH2: The roles in targeted therapy and mechanisms of resistance in breast cancer;Biomedicine & Pharmacotherapy;2024-06
3. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges;Frontiers in Immunology;2024-04-09
4. PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities;Pharmacological Research;2024-04
5. Targeting IL-6/STAT3 signaling abrogates EGFR-TKI resistance through inhibiting Beclin-1 dependent autophagy in HNSCC;Cancer Letters;2024-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3